Keywords: سانیتینیب; gemcitabine; sunitinib; synergistic; transitional cell carcinoma; vascular endothelial growth factor
مقالات ISI سانیتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: سانیتینیب; Sunitinib; Sutent; Adhesions; Anastomosis; Bursting strength; Cardiotoxicity; Echocardiogram; Hepatotoxicity; Rabbit; Safety
Keywords: سانیتینیب; Sunitinib; Overall survival; Progression-free survival; Surrogate end-point; Renal cell carcinoma;
Keywords: سانیتینیب; CT; MASS criteria; Neoadjuvant; Renal cell carcinoma; Sunitinib
Keywords: سانیتینیب; cost effectiveness; crossover; oncology; sunitinib; surviva;
Keywords: سانیتینیب; Renal insufficiency; Metastatic renal cell carcinoma; Sunitinib;
Keywords: سانیتینیب; renal cell carcinoma; prognosis; survival; sunitinib; sorafenib;
Keywords: سانیتینیب; Renal cell carcinoma; Sorafenib; Pazopanib; Everolimus; Sunitinib; Bevacizumab; Axitinib; Antiangiogenic therapy; Treatment algorithm;
Keywords: سانیتینیب; Sarcoma; Solitary fibrous tumour; Pazopanib; Sunitinib; Tyrosine kinase; Chemotherapy;
Keywords: سانیتینیب; kidney; carcinoma; renal cell; sunitinib; drug-related side effects and adverse reactions; drug administration scheduleAE, adverse event; AS, alternative schedule; LDH, lactate dehydrogenase; mRCC, metastatic renal cell cancer; OS, overall survival; PFS,
Keywords: سانیتینیب; Metastatic renal cell cancer; Sunitinib; Elderly; Lymphopenia; Prognosis
Keywords: سانیتینیب; Sunitinib; Cardiotoxicity; Cancer treatment-related hypertension; Reversibility of cardiotoxic events
Keywords: سانیتینیب; Renal cell carcinoma; Non-clear cell; Metastatic; Papillary; Chromophobe; Systemic therapy; Targeted therapy; Temsirolimus; Sunitinib; Sorafenib
Keywords: سانیتینیب; Cancer; Gastrointestinal perforation; Sorafenib; Sunitinib; Vandetanib; Axitinib; Pazopanib; Cediranib; Meta-analysis;
Keywords: سانیتینیب; IL-6; Angiogenesis; VEGF; STAT3; HIF-1α; Bevacizumab; Sunitinib; Siltuximab;
Keywords: سانیتینیب; BSA; bovine serum albumin; CI; combination index; DRI; dose-reduction index; DTNB; 5,5-dithio-bis (2-nitrobenzoic acid); DMSO; dimethyl sulfoxide; EAC; Ehrlich ascites carcinoma; FBS; fetal bovine serum; GIST; gastrointestinal stromal tumor; GSH; glutathi
Keywords: سانیتینیب; Sunitinib; Meta-analysis; Cardiovascular toxicities; Hypertension; Left ventricular dysfunction
Keywords: سانیتینیب; Angiogenesis model; Pericyte; Imatinib; Sunitinib; Endoglin; Drug screening; Blood vessel maturation;
Keywords: سانیتینیب; Renal cell carcinoma; Sequential therapy; Survival; Sunitinib; Sorafenib; Everolimus; Bevacizumab; Axitinib; Temsirolimus; Third-line;
Keywords: سانیتینیب; Biomarker; Contractility; Erlotinib; FCCP; Isolated heart; Isoproterenol; Rat; Sorafenib; Sunitinib; Verapamil;
Keywords: سانیتینیب; Angiogenesis; Castration resistant prostate cancer; Vascular endothelial growth factor; Bevacizumab; Sunitinib; Cabozantinib;
Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma
Keywords: سانیتینیب; Antibiotics; Pazopanib; Sunitinib; VEGF-TKI;
Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?
Keywords: سانیتینیب; mRCC; Intermediate risk; Overall survival; Poor risk; Sunitinib;
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254)
Keywords: سانیتینیب; Sunitinib; Progression-free survival; Persistent or recurrent clear cell ovarian carcinoma;
Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma
Keywords: سانیتینیب; Sunitinib; Dose-escalation; Renal cell carcinoma; Disease progression; Toxicity;
Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST)
Keywords: سانیتینیب; Gastrointestinal stromal tumor; Imatinib; Sunitinib; Prognosis; Older age;
Topical Sunitinib ointment alleviates Psoriasis-like inflammation by inhibiting the proliferation and apoptosis of keratinocytes
Keywords: سانیتینیب; Psoriasis; Sunitinib; Imiquimod; Hacat cells; Stat3;
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results
Keywords: سانیتینیب; Adjuvant; Disease-free survival; Renal cell carcinoma; Sunitinib;
Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis
Keywords: سانیتینیب; Adjuvant chemotherapy; Renal cell carcinoma; Pazopanib; Sunitinib; Sorafenib; Tyrosine kinase inhibitors;
Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib
Keywords: سانیتینیب; Renal cell carcinoma; AXL; Sunitinib; Cabozantinib; Prognostic biomarker;
pH-controlled sunitinib anticancer release from magnetic chitosan nanoparticles crosslinked with κ-carrageenan
Keywords: سانیتینیب; Magnetic; pH-responsive; Chitosan; Sunitinib;
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Keywords: سانیتینیب; Cabozantinib; First-line; Sunitinib; IMDC risk groups; Advanced renal cell carcinoma;
A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs
Keywords: سانیتینیب; Angiogenesis inhibitors; DLL4; Human umbilical vein endothelial cell; In vitro 3D model; Microvessel; Notch; Sorafenib; Sprouting angiogenesis; Sunitinib; Vascular endothelial growth factor; 3D; three-dimensional; BSA; bovine serum albumin; CLSM; confocal
Increased Afterload Augments Sunitinib-Induced Cardiotoxicity in an Engineered Cardiac Microtissue Model
Keywords: سانیتینیب; afterload; apoptosis; cardiotoxicity; sunitinib; tissue engineering; toxicology; tyrosine kinase inhibitors; 2D; 2-dimensional; 3D; 3-dimensional; AICAR; 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside; AMPK; adenosine monophosphate-activated protein
DNA binding of sunitinib: Spectroscopic evidence via circular dichroism and nuclear magnetic resonance
Keywords: سانیتینیب; Sunitinib; Circular dichroism; Induced circular dichroism; 1H NMR; Stauration transfer; DNA;
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study
Keywords: سانیتینیب; Sunitinib; Neuroendocrine tumors; Pancreas; Progressive disease; Target therapy;
Development of a novel conjugatable sunitinib analogue validated through in vitro and in vivo preclinical settings
Keywords: سانیتینیب; Sunitinib; Sunitinib conjugatable analogue; In vitro cytotoxicity; In vivo pharmacokinetics; Analytical methodology;
Analytical aspects of sunitinib and its geometric isomerism towards therapeutic drug monitoring in clinical routine
Keywords: سانیتینیب; Sunitinib; Z/E-isomerization; TDM; Mass spectrometry;
Multi-parameter MRI to investigate vasculature modulation and photo-thermal ablation combination therapy against cancer
Keywords: سانیتینیب; Photothermal therapy; Reduced graphene oxide; Nanoparticles; Magnetic resonance imaging; Hyperthermia; ADC; apparent diffusion coefficient; AFM; atomic force microscopy; BSA; bovine serum albumin; C18PMG; poly(maleic anhydride-alt-1-octadecene); DAPI; 4â
Sunitinib induces hepatocyte mitochondrial damage and apoptosis in mice
Keywords: سانیتینیب; Sunitinib; Hepatotoxicity; Mitochondrial toxicity; Reactive oxygen species (ROS); Apoptosis; PGC-1α;
Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma
Keywords: سانیتینیب; Carcinoma; Dose escalation; Metastasis; Renal cell; Sunitinib;
Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma
Keywords: سانیتینیب; DNA damage repair; Fumarate hydratase; Hereditary leiomyomatosis and renal cell cancer; Pazopanib; Sunitinib;
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
Keywords: سانیتینیب; mRCC; Dose reduction; Toxicity; Survival; Sunitinib; Pazopanib; First-line; Second-line;
Original ResearchSurgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: AÂ prospective cohort study
Keywords: سانیتینیب; Metastatic gastrointestinal stromal tumors; GIST; Sunitinib; Glivec;
Original research articleHPLC-UV method for simultaneous determination of MK-1775 and AZD-7762 in both acetonitrile-aqueous solution and mouse plasma
Keywords: سانیتینیب; MK; MK-1775; AZD; AZD-7762; SUN; sunitinib; ACN; acetonitrile; SPE; solid phase extraction; LOD; limit of detection; LOQ; limit of quantification; MK-1775; AZD-7762; Sunitinib; HPLC-UV; Solid phase extraction; Mouse plasma;
In vitro evaluation of sunitinib loaded bioresorbable microspheres for potential application in arterial chemoembolization
Keywords: سانیتینیب; Bioresorbable microspheres; Sunitinib; Anti-angiogenic; Drug release; Chemoembolization;
Clinical TrialA multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study
Keywords: سانیتینیب; Thyroid carcinoma; Sunitinib; Phase II;
Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations
Keywords: سانیتینیب; Sweden; Renal cell carcinoma; Targeted therapy; Sunitinib; Survival;
Design, synthesis and anticancer activity of N-(1-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)-1-oxo-3-phenylpropan-2-yl derivatives
Keywords: سانیتینیب; Dibenzo[b,f][1,4]thiazepin; Synthesis; Anticancer activity; Sirtuins; Sunitinib;
Electrochemistry of conjugated planar anticancer molecules: Irinotecan and Sunitinib
Keywords: سانیتینیب; Anticancer molecule; Electrochemistry; Irinotecan; Sunitinib; Electronic spectra;